Tirzepatide for Sleep Apnea: Newest Studies Show Major Relief for OSA in Men with Obesity Obstructive sleep apnea (OSA) affects millions of men, especially those carrying extra weight, leading to poor sleep, daytime fatigue, low testosterone, and increased cardiometabolic risks. The newest phase 3 studies on **tirzepatide**—the dual GIP/GLP-1 agonist already popular for weight loss—demonstrate…
Read more
Tirzepatide for Sleep Apnea: Newest Studies Show Major Relief for OSA in Men with Obesity




















































